drugset
drugset / Trial / NCT01390714

Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects

NCT01390714 ↗

Phase 1 Completed 30 enrolled Eisai Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects

Timeline

Start
2011-07
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZELOPRAZOLE Small molecule 20 mg Oral
Subject AZELOPRAZOLE Small molecule 40 mg Oral
Subject AZELOPRAZOLE Small molecule 80 mg Oral

Indications

gastroesophageal reflux disease